Churbz, based on Gerald's numerous statements that we won't conduct a RS at these levels in order to uplist, I think it's reasonable to expect the max RS we might see is perhaps 1:10 with the share price $0.25 or higher. I certainly believe there are catalysts planned to get us to that level, or possibly quite a lot higher. Gerald has also commented multiple times we might not need a RS at all. I think the reality lies somewhere in between these two statements. I think we'll probably have to do a RS but it will be somewhere between 1:4 and 1:10.

Although I understand the mechanics of a RS regarding the investment value before and after, the aspect you refer to is the leverage of having 10x the number of shares. But also think about how a new development might impact share price before or after a 1:10 RS. Let's say the development is approval of orphan drug status for one of our assets. If this development moves the share price upward by 5 cents with 800M shares issued, then theoretically the same value creation would move the share price by 50 cents with only 80M shares issued. And since we'd be trading on Nasdaq instead of OTC, such a development might move it significantly more than 50 cents, which would translate to more real leverage with our shares.

Also consider the possibility a few years down the road there would likely be forward splits of the stock, so as long-term shareholders we could recoup some or all of the share reduction in any RS done as part of uplisting.

I believe for the long-term investor, a RS will have little to no impact, for these reasons. GLTY